RAPTOR RESOURCES LIMITED - Announcements

0.00%

20.5¢

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

ResApp Health Limited is an Australia-based digital health company engaged in developing... ResApp Health Limited is an Australia-based digital health company engaged in developing smartphone applications for the diagnosis and management of respiratory disease. The Company provides point of care diagnostic solutions for telehealth that are integrated into existing platforms. The Company is focused on developing apps to provide instant clinical diagnostic tests and management tools directly to consumers and healthcare providers. The Company’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. Its products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Its obstructive sleep aponia screening test uses overnight breathing and snoring sounds recorded on a smartphone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

RAP	German Health-Economic Evaluation and Update on COPD Study		02/06/20	101.92KB	Share
RAP	ResApp to Present at TechKnow Invest Roadshow Webinar		11/05/20	95.13KB	Share
RAP	ResAppDx-EU in Use at COVID-19 Respiratory Clinic	PRICE SENSITIVE	11/05/20	102.33KB	Share
RAP	Change in substantial holding		11/05/20	211.34KB	Share
RAP	Section 708A Notice and Appendix 2A		06/05/20	328.37KB	Share
RAP	ResApp Receives Final Design Files for Hardware Devices	PRICE SENSITIVE	06/05/20	99.11KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/04/20	280.3KB	Share
RAP	Investor Presentation		22/04/20	9.11MB	Share
RAP	Appendix 3G		07/04/20	371.73KB	Share
RAP	Initial Director's Interest Notice		06/04/20	149.82KB	Share
RAP	ResApp Appoints Dr Michael Stein as a Non-Executive Director		06/04/20	99.79KB	Share
RAP	ResApp Announces SleepCheck, a Sleep Apnoea Screening App	PRICE SENSITIVE	01/04/20	949.54KB	Share
RAP	Final Director's Interest Notice		31/03/20	153.77KB	Share
RAP	Coviu and ResApp Complete Initial ResAppDx-EU Integration	PRICE SENSITIVE	30/03/20	191.25KB	Share
RAP	Resignation of Non-Executive Director		30/03/20	94.81KB	Share
RAP	ResApp Builds European Market Presence		26/03/20	110.18KB	Share
RAP	ResAppDx-EU to be Deployed on Phenix Health Telehealth App	PRICE SENSITIVE	24/03/20	118.88KB	Share
RAP	Investor Conference Call		11/03/20	97.29KB	Share
RAP	Update on US FDA De Novo Classification Request	PRICE SENSITIVE	11/03/20	98.82KB	Share
RAP	Direct-to-Consumer Product Update	PRICE SENSITIVE	11/03/20	94.71KB	Share
RAP	Trading Halt	PRICE SENSITIVE	09/03/20	205.62KB	Share
RAP	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	28/02/20	1.8MB	Share
RAP	Section 708A Notice and Appendix 2A		27/02/20	404.25KB	Share
RAP	Proposed issue of Securities - RAP		21/02/20	24.9KB	Share
RAP	ResApp Completes $5 Million Capital Raising	PRICE SENSITIVE	21/02/20	77.25KB	Share
RAP	TGA Approval for Adult Respiratory Disease Diagnosis	PRICE SENSITIVE	20/02/20	78.83KB	Share
RAP	Trading Halt	PRICE SENSITIVE	19/02/20	203.9KB	Share
RAP	Proposed issue of Securities - RAP		18/02/20	24.54KB	Share
RAP	Functional Testing of Handheld and Wearable Devices Complete	PRICE SENSITIVE	18/02/20	80.02KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/20	288.56KB	Share
RAP	Change of Director's Interest Notice x 4		20/12/19	541.97KB	Share
RAP	Appendix 3B		20/12/19	461.44KB	Share
RAP	Clinical Study of COPD Screening in Indigenous Australians	PRICE SENSITIVE	19/12/19	82.79KB	Share
RAP	ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate	PRICE SENSITIVE	12/12/19	74.53KB	Share
RAP	Results of Annual General Meeting		28/11/19	263.93KB	Share
RAP	Annual General Meeting Presentation		28/11/19	3.53MB	Share
RAP	ResAppDx-EU to be deployed on the Coviu Telehealth Platform	PRICE SENSITIVE	28/11/19	158.28KB	Share
RAP	2019 Letter to Shareholders		25/11/19	101.57KB	Share
RAP	ResApp Grants Option to Consumer Health Division of Sanofi	PRICE SENSITIVE	15/11/19	77.3KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/10/19	343.88KB	Share
RAP	Notice of Annual General Meeting		28/10/19	1.02MB	Share
RAP	Change of Registered Office		24/10/19	78.19KB	Share
RAP	ResApp Joins Startup Creasphere Digital Health Program	PRICE SENSITIVE	04/10/19	70.46KB	Share
RAP	Change of Principal Place of Business		03/10/19	81.66KB	Share
RAP	TGA Approval for Paediatric Respiratory Disease Diagnosis	PRICE SENSITIVE	02/10/19	74.6KB	Share
RAP	Trading Halt	PRICE SENSITIVE	01/10/19	203.32KB	Share
RAP	Pause In trading	PRICE SENSITIVE	01/10/19	115.77KB	Share
RAP	Positive Results from At-Home Sleep Apnoea Study	PRICE SENSITIVE	30/09/19	93.63KB	Share
RAP	ResAppDx-EU for Adult Respiratory Disease Receives CE Mark	PRICE SENSITIVE	26/09/19	81.44KB	Share
RAP	Investor Presentation September 2019		16/09/19	7.5MB	Share
RAP	Appendix 4G		28/08/19	207.51KB	Share
RAP	Corporate Governance Statement		28/08/19	131.78KB	Share
RAP	Appendix 4E and Annual Report	PRICE SENSITIVE	28/08/19	4.98MB	Share
RAP	ResApp Receives CE Mark for ResAppDx-EU	PRICE SENSITIVE	23/08/19	80KB	Share
RAP	Trading Halt	PRICE SENSITIVE	22/08/19	350.99KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	29/07/19	288.94KB	Share
RAP	Appendix 3B and Section 708A Notice		04/07/19	554.45KB	Share
RAP	At-Home Obstructive Sleep Apnoea Study Update		01/07/19	73.64KB	Share
RAP	Extension of CEO and Managing Director's Contract	PRICE SENSITIVE	19/06/19	74.74KB	Share
RAP	Investor Presentation June 2019		13/06/19	1.06MB	Share
RAP	ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate	PRICE SENSITIVE	12/06/19	68.4KB	Share
RAP	Paediatric Study Published In Peer-Reviewed Journal		06/06/19	75.06KB	Share
RAP	Appendix 3B		05/06/19	412.18KB	Share
RAP	Healthcare Leaders Appointed to Industry Advisory Board		05/06/19	79.12KB	Share
RAP	Market Clarification Announcement		30/05/19	152.3KB	Share
RAP	Hardware and Wearable Devices to Expand ResApp's Markets	PRICE SENSITIVE	29/05/19	84.43KB	Share
RAP	Appendix 3B		06/05/19	411.5KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/04/19	988.2KB	Share
RAP	Positive Results from Australian Adult Clinical Study	PRICE SENSITIVE	23/04/19	101.55KB	Share
RAP	ResApp Submits De Novo Application to the FDA	PRICE SENSITIVE	15/04/19	70.83KB	Share
RAP	Update on Australian Adult Study and FDA De Novo Submission	PRICE SENSITIVE	29/03/19	70.46KB	Share
RAP	TechKnow Invest Roadshow Presentation		19/03/19	809.07KB	Share
RAP	Updated Top-line Results from SMARTCOUGH-C-2 Study	PRICE SENSITIVE	18/03/19	83.12KB	Share
RAP	ResApp Receives R&D Advanced Overseas Finding	PRICE SENSITIVE	13/03/19	67.2KB	Share
RAP	Appendix 3B		11/03/19	407.55KB	Share
RAP	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	28/02/19	899.01KB	Share
RAP	Appendix 3B		25/02/19	407.68KB	Share
RAP	Appendix 3B		11/02/19	404.74KB	Share
RAP	ResApp to Host Investor Q&A Conference Call		04/02/19	68.37KB	Share
RAP	Quarterly Update and Appendix 4C	PRICE SENSITIVE	29/01/19	332.81KB	Share
RAP	ResApp Submits CE Mark Technical File	PRICE SENSITIVE	02/01/19	73.87KB	Share
RAP	Results of Annual General Meeting		15/11/18	226.63KB	Share
RAP	2018 Letter to Shareholders		15/11/18	95.58KB	Share
RAP	ResApp Clears Major Milestone for CE and TGA with ISO 13485	PRICE SENSITIVE	14/11/18	70.31KB	Share
RAP	ResApp Receives Notice of Allowance for Core Patent in Japan	PRICE SENSITIVE	05/11/18	66.78KB	Share
RAP	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	205.7KB	Share
RAP	CEO's Prepared Statement for Investor Conference Call		31/10/18	95.34KB	Share
RAP	ResApp Presentation at TechKnow Invest Roadshow		30/10/18	4.01MB	Share
RAP	Investor Conference Call		30/10/18	79.15KB	Share
RAP	Reinstatement to Official Quotation	PRICE SENSITIVE	30/10/18	213.27KB	Share
RAP	Positive Preliminary Results from SMARTCOUGH-C-2 Study	PRICE SENSITIVE	30/10/18	92.59KB	Share
RAP	Voluntary Suspension Update		29/10/18	67.7KB	Share
RAP	Voluntary Suspension	PRICE SENSITIVE	24/10/18	204.82KB	Share
RAP	Trading Halt	PRICE SENSITIVE	22/10/18	204.54KB	Share
RAP	Response to ASX Price Query	PRICE SENSITIVE	17/10/18	525.37KB	Share
RAP	Notice of Annual General Meeting		15/10/18	554.1KB	Share
RAP	Positive Results for Prospective Sleep Apnoea Clinical Study	PRICE SENSITIVE	11/10/18	84.73KB	Share
RAP	Trading Halt	PRICE SENSITIVE	09/10/18	545.05KB	Share
RAP	Recruitment Completed in Prospective Sleep Apnoea Study	PRICE SENSITIVE	02/10/18	68.45KB	Share
RAP	Appendix 4G		28/09/18	208.92KB	Share

RAP German Health-Economic Evaluation and Update on COPD Study
02/06/20		101.92KB	Share
RAP ResApp to Present at TechKnow Invest Roadshow Webinar
11/05/20		95.13KB	Share
RAP ResAppDx-EU in Use at COVID-19 Respiratory Clinic
11/05/20	PRICE SENSITIVE	102.33KB	Share
RAP Change in substantial holding
11/05/20		211.34KB	Share
RAP Section 708A Notice and Appendix 2A
06/05/20		328.37KB	Share
RAP ResApp Receives Final Design Files for Hardware Devices
06/05/20	PRICE SENSITIVE	99.11KB	Share
RAP Quarterly Update and Appendix 4C
30/04/20	PRICE SENSITIVE	280.3KB	Share
RAP Investor Presentation
22/04/20		9.11MB	Share
RAP Appendix 3G
07/04/20		371.73KB	Share
RAP Initial Director's Interest Notice
06/04/20		149.82KB	Share
RAP ResApp Appoints Dr Michael Stein as a Non-Executive Director
06/04/20		99.79KB	Share
RAP ResApp Announces SleepCheck, a Sleep Apnoea Screening App
01/04/20	PRICE SENSITIVE	949.54KB	Share
RAP Final Director's Interest Notice
31/03/20		153.77KB	Share
RAP Coviu and ResApp Complete Initial ResAppDx-EU Integration
30/03/20	PRICE SENSITIVE	191.25KB	Share
RAP Resignation of Non-Executive Director
30/03/20		94.81KB	Share
RAP ResApp Builds European Market Presence
26/03/20		110.18KB	Share
RAP ResAppDx-EU to be Deployed on Phenix Health Telehealth App
24/03/20	PRICE SENSITIVE	118.88KB	Share
RAP Investor Conference Call
11/03/20		97.29KB	Share
RAP Update on US FDA De Novo Classification Request
11/03/20	PRICE SENSITIVE	98.82KB	Share
RAP Direct-to-Consumer Product Update
11/03/20	PRICE SENSITIVE	94.71KB	Share
RAP Trading Halt
09/03/20	PRICE SENSITIVE	205.62KB	Share
RAP Appendix 4D and Half Year Financial Report
28/02/20	PRICE SENSITIVE	1.8MB	Share
RAP Section 708A Notice and Appendix 2A
27/02/20		404.25KB	Share
RAP Proposed issue of Securities - RAP
21/02/20		24.9KB	Share
RAP ResApp Completes $5 Million Capital Raising
21/02/20	PRICE SENSITIVE	77.25KB	Share
RAP TGA Approval for Adult Respiratory Disease Diagnosis
20/02/20	PRICE SENSITIVE	78.83KB	Share
RAP Trading Halt
19/02/20	PRICE SENSITIVE	203.9KB	Share
RAP Proposed issue of Securities - RAP
18/02/20		24.54KB	Share
RAP Functional Testing of Handheld and Wearable Devices Complete
18/02/20	PRICE SENSITIVE	80.02KB	Share
RAP Quarterly Update and Appendix 4C
31/01/20	PRICE SENSITIVE	288.56KB	Share
RAP Change of Director's Interest Notice x 4
20/12/19		541.97KB	Share
RAP Appendix 3B
20/12/19		461.44KB	Share
RAP Clinical Study of COPD Screening in Indigenous Australians
19/12/19	PRICE SENSITIVE	82.79KB	Share
RAP ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate
12/12/19	PRICE SENSITIVE	74.53KB	Share
RAP Results of Annual General Meeting
28/11/19		263.93KB	Share
RAP Annual General Meeting Presentation
28/11/19		3.53MB	Share
RAP ResAppDx-EU to be deployed on the Coviu Telehealth Platform
28/11/19	PRICE SENSITIVE	158.28KB	Share
RAP 2019 Letter to Shareholders
25/11/19		101.57KB	Share
RAP ResApp Grants Option to Consumer Health Division of Sanofi
15/11/19	PRICE SENSITIVE	77.3KB	Share
RAP Quarterly Update and Appendix 4C
30/10/19	PRICE SENSITIVE	343.88KB	Share
RAP Notice of Annual General Meeting
28/10/19		1.02MB	Share
RAP Change of Registered Office
24/10/19		78.19KB	Share
RAP ResApp Joins Startup Creasphere Digital Health Program
04/10/19	PRICE SENSITIVE	70.46KB	Share
RAP Change of Principal Place of Business
03/10/19		81.66KB	Share
RAP TGA Approval for Paediatric Respiratory Disease Diagnosis
02/10/19	PRICE SENSITIVE	74.6KB	Share
RAP Trading Halt
01/10/19	PRICE SENSITIVE	203.32KB	Share
RAP Pause In trading
01/10/19	PRICE SENSITIVE	115.77KB	Share
RAP Positive Results from At-Home Sleep Apnoea Study
30/09/19	PRICE SENSITIVE	93.63KB	Share
RAP ResAppDx-EU for Adult Respiratory Disease Receives CE Mark
26/09/19	PRICE SENSITIVE	81.44KB	Share
RAP Investor Presentation September 2019
16/09/19		7.5MB	Share
RAP Appendix 4G
28/08/19		207.51KB	Share
RAP Corporate Governance Statement
28/08/19		131.78KB	Share
RAP Appendix 4E and Annual Report
28/08/19	PRICE SENSITIVE	4.98MB	Share
RAP ResApp Receives CE Mark for ResAppDx-EU
23/08/19	PRICE SENSITIVE	80KB	Share
RAP Trading Halt
22/08/19	PRICE SENSITIVE	350.99KB	Share
RAP Quarterly Update and Appendix 4C
29/07/19	PRICE SENSITIVE	288.94KB	Share
RAP Appendix 3B and Section 708A Notice
04/07/19		554.45KB	Share
RAP At-Home Obstructive Sleep Apnoea Study Update
01/07/19		73.64KB	Share
RAP Extension of CEO and Managing Director's Contract
19/06/19	PRICE SENSITIVE	74.74KB	Share
RAP Investor Presentation June 2019
13/06/19		1.06MB	Share
RAP ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate
12/06/19	PRICE SENSITIVE	68.4KB	Share
RAP Paediatric Study Published In Peer-Reviewed Journal
06/06/19		75.06KB	Share
RAP Appendix 3B
05/06/19		412.18KB	Share
RAP Healthcare Leaders Appointed to Industry Advisory Board
05/06/19		79.12KB	Share
RAP Market Clarification Announcement
30/05/19		152.3KB	Share
RAP Hardware and Wearable Devices to Expand ResApp's Markets
29/05/19	PRICE SENSITIVE	84.43KB	Share
RAP Appendix 3B
06/05/19		411.5KB	Share
RAP Quarterly Update and Appendix 4C
30/04/19	PRICE SENSITIVE	988.2KB	Share
RAP Positive Results from Australian Adult Clinical Study
23/04/19	PRICE SENSITIVE	101.55KB	Share
RAP ResApp Submits De Novo Application to the FDA
15/04/19	PRICE SENSITIVE	70.83KB	Share
RAP Update on Australian Adult Study and FDA De Novo Submission
29/03/19	PRICE SENSITIVE	70.46KB	Share
RAP TechKnow Invest Roadshow Presentation
19/03/19		809.07KB	Share
RAP Updated Top-line Results from SMARTCOUGH-C-2 Study
18/03/19	PRICE SENSITIVE	83.12KB	Share
RAP ResApp Receives R&D Advanced Overseas Finding
13/03/19	PRICE SENSITIVE	67.2KB	Share
RAP Appendix 3B
11/03/19		407.55KB	Share
RAP Appendix 4D and Half Year Financial Report
28/02/19	PRICE SENSITIVE	899.01KB	Share
RAP Appendix 3B
25/02/19		407.68KB	Share
RAP Appendix 3B
11/02/19		404.74KB	Share
RAP ResApp to Host Investor Q&A Conference Call
04/02/19		68.37KB	Share
RAP Quarterly Update and Appendix 4C
29/01/19	PRICE SENSITIVE	332.81KB	Share
RAP ResApp Submits CE Mark Technical File
02/01/19	PRICE SENSITIVE	73.87KB	Share
RAP Results of Annual General Meeting
15/11/18		226.63KB	Share
RAP 2018 Letter to Shareholders
15/11/18		95.58KB	Share
RAP ResApp Clears Major Milestone for CE and TGA with ISO 13485
14/11/18	PRICE SENSITIVE	70.31KB	Share
RAP ResApp Receives Notice of Allowance for Core Patent in Japan
05/11/18	PRICE SENSITIVE	66.78KB	Share
RAP Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	205.7KB	Share
RAP CEO's Prepared Statement for Investor Conference Call
31/10/18		95.34KB	Share
RAP ResApp Presentation at TechKnow Invest Roadshow
30/10/18		4.01MB	Share
RAP Investor Conference Call
30/10/18		79.15KB	Share
RAP Reinstatement to Official Quotation
30/10/18	PRICE SENSITIVE	213.27KB	Share
RAP Positive Preliminary Results from SMARTCOUGH-C-2 Study
30/10/18	PRICE SENSITIVE	92.59KB	Share
RAP Voluntary Suspension Update
29/10/18		67.7KB	Share
RAP Voluntary Suspension
24/10/18	PRICE SENSITIVE	204.82KB	Share
RAP Trading Halt
22/10/18	PRICE SENSITIVE	204.54KB	Share
RAP Response to ASX Price Query
17/10/18	PRICE SENSITIVE	525.37KB	Share
RAP Notice of Annual General Meeting
15/10/18		554.1KB	Share
RAP Positive Results for Prospective Sleep Apnoea Clinical Study
11/10/18	PRICE SENSITIVE	84.73KB	Share
RAP Trading Halt
09/10/18	PRICE SENSITIVE	545.05KB	Share
RAP Recruitment Completed in Prospective Sleep Apnoea Study
02/10/18	PRICE SENSITIVE	68.45KB	Share
RAP Appendix 4G
28/09/18		208.92KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

RAPTOR RESOURCES LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available